BT57 · Ointment format

Preliminary concept

A richer ointment format
for external skin comfort.

A fermentation-derived BT57 ointment concept designed to support barrier integrity, hydration, and comfort for dry or environmentally stressed external skin.

Include in sample kit Request reviewed technical information

Sample availability, formats, eligibility, and shipping regions are confirmed after review.

Forest tube representing the preliminary fermentation-derived BT57 ointment concept
Concept presentation · Not final retail packaging
Evidence-safe overview

Barrier and hydration support
in a smooth ointment.

BT57 is a preliminary fermentation-derived concept intended for dry or environmentally stressed external skin.

The ointment direction combines a spreadable texture with barrier, hydration, and comfort support. Active identity, formula details, target species, final claims, and regional positioning are confirmed during development.

Preliminary formulation

Typical categories,
not a consumer label.

These categories describe an early formulation direction. Final ingredients, concentrations, and labeling remain subject to development and review.

  • 01Fermentation-derived BT57 materialConcept material subject to identity confirmation
  • 02Natural oilsSunflower or coconut are example directions
  • 03GlycerinHumectant direction
  • 04Shea-butter or wax texture systemOintment-format support
  • 05Product-protection systemSubject to formulation review
  • 06AntioxidantStability direction
Physical direction

A smooth, semi-solid
ointment profile.

Appearance
Smooth, semi-solid ointment
Color
Off-white to pale beige
Texture
Homogeneous and spreadable
Use direction
Dry or environmentally stressed external skin
Potential packaging
Jars or tubes
Storage direction
15–25°C preferred; keep tightly closed and protect from sunlight, excessive heat, and freezing
Directions and safety

A precise external-use
direction.

Apply a thin layer to clean, dry external skin and massage until evenly distributed; use 1–3 times daily or as directed by a veterinarian.

  • External use only.
  • Discontinue use if an adverse reaction occurs.
  • Species suitability is confirmed during development.
Private-label pathway

Explore BT57 against
your formulation brief.

Include the concept in a qualified sample request and tell us about your target market, preferred format, and development timing.

Request BT57 samples